Boston Scientific at outperform by Bear Stearns

Bear Stearns analyst Rick Wise gave Boston Scientific Corp. an outperform rating following the company's analyst meeting. According to Wise, the discussions were generally positive in substance and tone. The Food and Drug Administration warning resolution timeline is on track, and Boston maintains robust product pipelines with several key product launches expected in 2007. The company had strong cash flow for the quarter of about $480 million. Shares of the Natick, Mass.-based medical device company were down 25 cents, or 1.48%, at $16.64. (NYSE: BSX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.